List of Excipients in Branded Drug PEMETREXED

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Hospira Inc	PEMETREXED	pemetrexed	0409-0020	MONOTHIOGLYCEROL
Hospira Inc	PEMETREXED	pemetrexed	0409-0020	SODIUM HYDROXIDE
Hospira Inc	PEMETREXED	pemetrexed	0409-0020	WATER
Hospira Inc	PEMETREXED	pemetrexed	0409-1045	MONOTHIOGLYCEROL

Generic Drugs Containing PEMETREXED

Company	Ingredient	NDC	Excipient
Baxter Healthcare Company	pemetrexed	0338-0720	HYDROCHLORIC ACID
Baxter Healthcare Company	pemetrexed	0338-0720	MANNITOL
Baxter Healthcare Company	pemetrexed	0338-0720	SODIUM HYDROXIDE
Accord Healthcare Inc	pemetrexed	16729-229	HYDROCHLORIC ACID

What are the Most Frequently-Used Excipients in PEMETREXED?

# Of NDCs	Excipient
29	HYDROCHLORIC ACID
29	MANNITOL
29	SODIUM HYDROXIDE

Pemetrexed Excipient Strategy and Commercial Opportunities

Last updated: August 6, 2026

Pemetrexed is an established intravenous antifolate with limited opportunity for conventional composition-of-matter protection but meaningful commercial potential in formulation, packaging, administration, and supply-chain improvements. The incumbent product, ALIMTA, is a lyophilized pemetrexed disodium injection reconstituted with preservative-free 0.9% sodium chloride. The strongest opportunities are ready-to-use presentations, improved reconstitution, reduced preparation time, lower extractables risk, and globally scalable generic formulations.

What excipients are used in pemetrexed injection?

The reference pemetrexed product is a sterile, preservative-free lyophilized powder. Its principal excipient is mannitol. Hydrochloric acid and sodium hydroxide are used for pH adjustment. The product is supplied in single-dose vials and reconstituted before intravenous infusion (U.S. Food and Drug Administration [FDA], 2024a).

Component	Function	Commercial relevance
Pemetrexed disodium	Active pharmaceutical ingredient	Cytotoxic antifolate
Mannitol	Bulking agent and lyophilization aid	Supports cake structure and vial recovery
Hydrochloric acid	pH adjustment	Controls solution stability
Sodium hydroxide	pH adjustment	Controls solution stability
Nitrogen or other headspace control, where used	Oxidation mitigation	Packaging and stability consideration
Type I glass vial	Primary container	Controls adsorption, extractables, and sterility risk
Elastomeric stopper and aluminum seal	Container closure	Important for particulate and leachable control

Mannitol is commercially attractive because it is familiar to regulators, available in pharmaceutical grades, and compatible with sterile lyophilization. Its use also reduces the need to introduce novel excipients into an oncology injectable product.

The formulation target is not simply chemical stability. A commercially viable product must also provide:

• Reliable cake formation after lyophilization.
• Rapid and complete reconstitution.
• Low visible and subvisible particulate formation.
• Acceptable pH and osmolality after dilution.
• Minimal adsorption to the vial, syringe, tubing, or infusion bag.
• Adequate stability during storage and administration.
• Compatibility with hospital compounding workflows.

How does the pemetrexed reference formulation work?

Pemetrexed disodium is supplied as a lyophilized powder because the solid state offers better storage and transport stability than a ready-to-use aqueous solution. The vial is reconstituted with preservative-free 0.9% sodium chloride and then diluted for intravenous administration. The FDA label specifies a 10-minute infusion and provides product-specific reconstitution and dilution instructions (FDA, 2024a).

The formulation has several practical characteristics:

1. It avoids preservatives in a cytotoxic injectable.
2. It uses a conventional and widely accepted lyophilization excipient.
3. It limits the number of formulation components.
4. It shifts some preparation burden to the hospital pharmacy.
5. It requires controlled handling because pemetrexed is a hazardous drug.

The low-excipient design reduces regulatory complexity but leaves room for process and presentation improvements. A generic manufacturer can compete without changing the core formulation, while a differentiated product would need to demonstrate a meaningful benefit in preparation, stability, administration, or waste reduction.

What formulation patents protect pemetrexed products?

The principal pemetrexed compound and early use patents are historically associated with Eli Lilly and include U.S. Patent Nos. 5,344,932 and 5,618,845. Those foundational rights are no longer the main barrier to ordinary pemetrexed injection development. Commercial protection now depends more heavily on regulatory exclusivity, product-specific listings, formulation claims, manufacturing processes, device claims, and market access agreements than on the original pemetrexed compound patents.

Patent category	Commercial status	Relevance to new products
Pemetrexed compound patents	Historical core protection	Limited barrier to current generic entry
Mesothelioma and NSCLC method patents	Largely historical or narrow by jurisdiction	May affect label strategy and litigation history
Lyophilized formulation patents	Potentially relevant if unexpired and claim-specific	Could cover excipient ratios, pH, moisture, or reconstitution
Ready-to-use solution patents	Potentially relevant	Main barrier for liquid presentations
Container or administration patents	Product-specific	May protect bags, syringes, connectors, or closed-transfer systems
Manufacturing-process patents	Potentially relevant	Can restrict crystallization, drying, impurity control, or scale-up
Pediatric exclusivity	Historical U.S. extension	Not a current substitute for patent protection

The principal diligence issue is claim scope. A patent covering “pemetrexed plus mannitol” may be difficult to enforce if the claim is narrow, already expired, or vulnerable to prior-art challenges. A patent covering a specific concentration range, residual moisture level, reconstitution time, or ready-to-use stability profile may have more practical value if the product depends on those parameters.

A commercial formulation program should review:

• U.S. patents and published applications.
• European and national-phase counterparts.
• Patent term adjustment and pediatric extensions.
• Orange Book-listed patents.
• Paragraph IV certifications.
• Patent litigation involving the proposed dosage form.
• Freedom to operate for excipients, bags, syringes, and transfer devices.

What is the FDA regulatory status of pemetrexed?

Pemetrexed is an FDA-approved small-molecule oncology drug. The reference product, ALIMTA, was approved for malignant pleural mesothelioma in combination with cisplatin and for nonsquamous non-small-cell lung cancer in several treatment settings (FDA, 2024a).

Generic pemetrexed injections are approved through the abbreviated new drug application pathway. An ANDA applicant generally must demonstrate pharmaceutical equivalence and bioequivalence or otherwise satisfy the applicable product-specific requirements. For an injectable solution or reconstituted lyophilized product, the regulatory focus includes sterility, particulate matter, visible clarity, impurity profile, container closure integrity, stability, and labeling consistency.

What does the Orange Book status mean for pemetrexed?

The Orange Book remains relevant for reference-listed-drug identification, patent listings, and certification strategy. The key commercial distinction is between:

• A conventional generic that matches the reference presentation.
• A product with a different formulation or delivery system.
• A product seeking an alternative dosage form or administration method.

A standard pemetrexed lyophilized vial may qualify for a comparatively direct ANDA strategy. A ready-to-use liquid, prefilled syringe, or novel infusion bag can trigger more complex formulation, stability, device, and regulatory questions. The more extensively the product departs from the reference presentation, the greater the risk that an ANDA will not be sufficient.

When does pemetrexed lose exclusivity?

Pemetrexed’s original U.S. compound and early method-of-use exclusivity periods have expired. The market is therefore primarily genericized, subject to any jurisdiction-specific patent, regulatory, contractual, or product-specific restriction.

Milestone	Approximate timing or status
Original U.S. compound patent family	Historical protection; no longer the principal market barrier
ALIMTA FDA approval	2004
Generic U.S. development	Mature market with multiple approved or marketed products
Current primary barrier	Formulation, manufacturing, device, supply, and commercial execution
Biosimilar exclusivity	Not applicable
Conventional generic launch risk	High where an approved, scalable formulation is available

The exact commercial launch date differs by market because patent settlements, national litigation, tender access, and local registrations affect entry. In the United States, a generic applicant may use a Paragraph IV certification when it challenges an Orange Book patent. Such a challenge can produce litigation, a 30-month stay in qualifying circumstances, or a settlement permitting an agreed launch date.

Which companies are challenging or competing with pemetrexed?

Competition comes from both generic injectable manufacturers and branded alternatives in nonsquamous NSCLC and mesothelioma.

Generic pemetrexed manufacturers

The competitive field can include large global generic companies, specialty injectable manufacturers, contract development and manufacturing organizations, and regional suppliers. Competitive advantage depends on more than abbreviated approval. Buyers evaluate:

• Vial fill size and dose flexibility.
• Reliable supply of sterile pemetrexed API.
• Shortage history.
• Purchase-contract performance.
• Wastage.
• Reconstitution time.
• Hospital pharmacy familiarity.
• Global registration coverage.

Therapeutic competitors

Pemetrexed competes clinically with other chemotherapy and immuno-oncology regimens. In nonsquamous NSCLC, treatment choices can include platinum combinations, immune checkpoint inhibitors, targeted therapies for biomarker-defined populations, and maintenance regimens. In mesothelioma, pemetrexed remains part of established treatment protocols, but immunotherapy has expanded the competitive environment.

This creates two different formulation markets:

1. A mature generic market where price and supply reliability dominate.
2. A differentiated oncology market where administration efficiency and integration with combination therapy can justify a premium.

What excipient strategies can improve pemetrexed products?

Conventional lyophilized formulation

The lowest-risk strategy is to retain mannitol and optimize the lyophilization cycle, moisture content, reconstitution time, and vial fill. This approach supports an ANDA or equivalent generic pathway and minimizes excipient-related safety questions.

Potential improvements include:

• Optimized mannitol concentration.
• Controlled residual moisture.
• Reduced cake collapse.
• Faster reconstitution.
• Lower vial-to-vial variability.
• Improved recovery from the container.
• Better stability after reconstitution and dilution.

The commercial limitation is substitutability. A product that is chemically equivalent but operationally indistinguishable may compete mainly on price.

Ready-to-use aqueous solution

A liquid product could reduce pharmacy preparation time and lower occupational exposure during reconstitution. The formulation would require robust control of pH, oxidation, hydrolysis, precipitation, and container interaction.

Potential excipient classes include:

• Tonicity agents.
• Buffer systems.
• Chelating agents where justified.
• Antioxidants where compatible with the active ingredient and regulatory expectations.
• Solubilizing or stabilizing agents.

The main risk is that every additional excipient creates new compatibility and regulatory obligations. A buffered solution may also change the impurity profile or interact with infusion materials. The strongest commercial case is a product with extended refrigerated or room-temperature stability, low particulate burden, and a direct administration workflow.

Pre-filled syringe or ready-to-administer presentation

A prefilled syringe could reduce preparation steps and drug wastage. However, a cytotoxic injectable must address syringe material compatibility, dose flexibility, labeling, transport, cold-chain requirements, and safety-device integration.

The presentation is most attractive for fixed or frequently used doses. It is less attractive where patient dosing is individualized by body-surface area and pharmacy personnel must prepare variable volumes.

Ready-to-use infusion bag

A premixed bag can integrate with hospital administration systems and lower compounding workload. The product would require a validated bag material, compatible overwrap, controlled extractables and leachables, and stability through the labeled administration period.

Commercial value increases if the product can be supplied in multiple dose strengths or if the bag minimizes residual drug and preparation waste. The patent opportunity may lie in the combination of formulation, bag material, concentration, and stability period rather than in the excipient alone.

Closed-system transfer compatibility

Pemetrexed is handled under hazardous-drug controls. A formulation designed for compatibility with closed-system transfer devices, automated compounding systems, or pharmacy robotics could create a practical point of differentiation.

The relevant claims may involve:

• Low-foaming reconstitution.
• Controlled vial pressure.
• Reduced particulate generation.
• Compatible stopper penetration.
• Low adsorption to tubing.
• Stable concentration during transfer.
• Reduced residual volume.

These features may be more valuable to institutional buyers than a novel excipient.

How strong is the patent estate for pemetrexed excipients?

The patent estate is generally weaker for basic excipient substitution than for integrated delivery systems. Mannitol, sodium chloride, hydrochloric acid, and sodium hydroxide are established pharmaceutical materials. Broad claims directed only to their use with pemetrexed may face prior-art and obviousness challenges.

Stronger patent positions may arise from a narrow combination with measurable performance, such as:

• A specific pemetrexed concentration.
• A defined pH range.
• A specified residual moisture range.
• A defined reconstitution time.
• A liquid formulation stable for a stated period.
• A particular bag or syringe material.
• A reduced-degradation impurity profile.
• A manufacturing sequence that produces a distinct solid form or purity profile.

Patent strength should be assessed using claim breadth, demonstrated technical effect, prior art, enablement, and design-around options. A formulation patent with no clinically relevant or operational advantage may have limited licensing value even if it survives examination.

What manufacturing and IP barriers affect pemetrexed?

Pemetrexed is not difficult because the active ingredient is novel. It is difficult because sterile cytotoxic manufacturing has a narrow margin for process failure.

API and impurity control

Commercial developers must control:

• Related antifolate impurities.
• Residual solvents.
• Water content.
• Sodium content and counterion state.
• Particle-size distribution.
• Bioburden and endotoxin.
• Degradation during storage.

The API process may be protected by manufacturing patents or trade secrets even when the active ingredient is off patent. Consistent API quality is critical because small impurity changes can affect solution appearance, stability, and regulatory comparability.

Sterile fill-finish

Pemetrexed requires aseptic processing or an appropriately validated sterile manufacturing process. A cytotoxic facility must manage containment, cleaning validation, cross-contamination, operator protection, and waste handling.

A low-cost API strategy does not overcome a high-cost sterile-fill bottleneck. Partnerships with established oncology injectable manufacturers can reduce development time and improve tender credibility.

Container closure and transport

The product must maintain sterility and chemical quality throughout distribution. Key studies include:

• Container closure integrity.
• Freeze-drying stress.
• Shipping vibration.
• Temperature excursions.
• Light exposure.
• Stopper compatibility.
• Extractables and leachables.
• Particulate generation.

A formulation that performs well in a vial may fail after transfer to an infusion bag or syringe. Commercial development should test the complete administration pathway, not only the finished vial.

What licensing deals could create value?

Pemetrexed licensing opportunities are more likely to involve technology or market access than core molecule rights.

Potential deal structures include:

Deal type	Licensor asset	Buyer rationale
Formulation license	Ready-to-use liquid or improved lyophilized product	Reduce development time
Manufacturing license	Sterile fill-finish process or containment method	Access capacity and technical expertise
Device license	Prefilled syringe, bag, or transfer system	Create administration differentiation
Regional commercialization	Local registration and tender rights	Expand geographic coverage
API supply agreement	Qualified pemetrexed disodium source	Reduce supply risk
Co-development agreement	Oncology injectable platform	Share regulatory and manufacturing investment

Royalty rates are likely to be constrained in a mature generic market unless the licensed technology produces a clear economic benefit. The strongest negotiating assets are a granted patent with meaningful remaining term, validated stability data, regulatory acceptance, and a manufacturing process that is difficult to replicate.

What generic entry risks exist for differentiated pemetrexed products?

A conventional generic can enter quickly when API supply, sterile capacity, and regulatory documentation are available. A differentiated product faces more complex risks.

Product concept	Generic substitution risk	Principal barrier
Matching lyophilized vial	High	Price and supply competition
Improved lyophilized vial	Medium to high	Limited reimbursement premium
Ready-to-use liquid vial	Medium	Stability and regulatory pathway
Prefilled syringe	Medium	Dose variability and device validation
Premixed infusion bag	Medium	Bag compatibility and logistics
Closed-system optimized product	Lower if well protected	Device and workflow integration
Long-stability liquid product	Lower	Strong technical and commercial value

Hospital buyers may not pay a premium for a modest reconstitution improvement. The product must reduce labor, hazardous-drug exposure, waste, inventory complexity, or administration time. Pharmacy-and-therapeutics committees can also delay adoption if a new presentation requires changes to protocols or electronic ordering systems.

How does pemetrexed compare with other generic oncology injectables?

Pemetrexed has a favorable formulation profile because it can be supplied as a relatively simple lyophilized product. It does not require the complex protein stabilization used for biologics and is not subject to biosimilar interchangeability rules.

Attribute	Pemetrexed	Biologic oncology product
Regulatory pathway	Generic small-molecule pathway	Biosimilar or biologics pathway
Main dosage form	Lyophilized injectable	Often liquid or lyophilized biologic
Excipient burden	Relatively low	Often higher and more sensitive
Biosimilar risk	Not applicable	Material
Main differentiation	Preparation, packaging, supply	Clinical similarity, immunogenicity, device
Manufacturing barrier	Sterile cytotoxic production	Cell culture, purification, sterile fill
Price pressure	High	Variable, often lower after biosimilar entry

Compared with more unstable oncology injectables, pemetrexed offers a lower technical development burden. Compared with simple liquid generics, it offers more room for value through reconstitution and administration improvements.

What geographic opportunities exist for pemetrexed excipient products?

The United States and Europe are mature markets with established generic competition. Commercial opportunity may be stronger in markets where oncology infusion capacity is expanding and pharmacy labor is constrained.

Priority regions can include:

• North America, where hospital purchasing is highly price-sensitive but workflow improvements can support contracting.
• Europe, where national tenders and local reimbursement determine volume.
• Japan, where regulatory and packaging requirements can differ materially.
• China, where centralized procurement can compress price but increase volume potential.
• India, Latin America, and Southeast Asia, where local manufacturing and reliable supply can support registration and tender access.
• Middle East markets, where imported sterile injectables may face supply constraints.

Geographic expansion requires more than a global formulation. Differences in vial sizes, language, labeling, cold-chain requirements, local GMP expectations, and pharmacopoeial specifications can affect the business case.

What is the commercial outlook for pemetrexed excipient innovation?

The commercial outlook is strongest for products that solve a measurable hospital problem. The most defensible opportunity areas are:

1. Long-stability ready-to-use liquid.
2. Premixed infusion bags with validated in-use stability.
3. Low-waste, dose-flexible packaging.
4. Faster-reconstituting lyophilized vials.
5. Closed-system transfer compatibility.
6. Integrated supply and fill-finish services.
7. Regional products designed for oncology tender requirements.

A new excipient alone is unlikely to command a durable premium. A formulation platform that combines excipient selection, packaging, device compatibility, and validated workflow savings has a stronger business case.

Key Takeaways

• Pemetrexed is a mature generic small-molecule oncology product with limited remaining core-molecule exclusivity.
• The reference formulation uses a simple lyophilized system centered on mannitol, with hydrochloric acid and sodium hydroxide for pH adjustment.
• Conventional generic products face high price and substitution pressure.
• The best commercial opportunities are ready-to-use liquids, premixed bags, improved lyophilized vials, and administration-system compatibility.
• Formulation patents are strongest when they claim a measurable technical effect, not merely a known excipient combination.
• Sterile cytotoxic manufacturing, API consistency, container compatibility, and hospital workflow integration are major barriers.
• Biosimilar risk does not apply because pemetrexed is a small molecule.
• Licensing value is more likely to arise from formulation, device, manufacturing, or regional commercialization rights than from pemetrexed molecule rights.
• A premium product must reduce labor, exposure, preparation time, waste, or supply risk to compete in a mature market.

FAQs

Can mannitol be replaced in a pemetrexed formulation?

Yes, but replacement requires a demonstrated effect on cake structure, reconstitution, stability, impurity formation, and container compatibility. Common alternatives may create new regulatory and patent issues.

Is a liquid pemetrexed formulation commercially attractive?

Yes, if it provides meaningful refrigerated or room-temperature stability, reduces pharmacy preparation, and remains compatible with infusion bags and administration devices. Stability and cytotoxic handling requirements are the principal development barriers.

Does pemetrexed have biosimilar competition?

No. Pemetrexed is a chemically synthesized small molecule. Competition proceeds through generic drug pathways rather than biosimilar approval pathways.

Can a pemetrexed formulation receive new patent protection?

Potentially. Patentable subject matter may include specific excipient ratios, concentration ranges, stability profiles, packaging systems, manufacturing processes, or administration combinations. Broad claims to pemetrexed with conventional excipients are more vulnerable to prior art.

Which pemetrexed presentation has the highest commercial potential?

A ready-to-use or premixed presentation with extended stability and low waste has the strongest differentiation potential. A matching lyophilized vial has the lowest development risk but faces the most severe price competition.

References

1. European Medicines Agency. (2024). Alimta: Summary of product characteristics. https://www.ema.europa.eu/

2. U.S. Food and Drug Administration. (2024a). Alimta (pemetrexed for injection) prescribing information. https://www.accessdata.fda.gov/

3. U.S. Food and Drug Administration. (2024b). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

4. U.S. Food and Drug Administration. (2023). ANDAs for certain highly purified synthetic peptides guidance for industry. https://www.fda.gov/

5. U.S. Food and Drug Administration. (2020). Q1A(R2): Stability testing of new drug substances and products. https://www.fda.gov/

6. International Council for Harmonisation. (2022). Q3E guideline for extractables and leachables. https://www.ich.org/

7. U.S. Patent No. 5,344,932. (1994). N-substituted derivatives of glutamic acid. United States Patent and Trademark Office.

8. U.S. Patent No. 5,618,845. (1997). N-substituted derivatives of glutamic acid. United States Patent and Trademark Office.